Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse

NCT01632852 is registered in ClinicalTrials.gov with CSL Limited as lead sponsor.

NCT NCT01632852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01632852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Lead sponsor
CSL Limited
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
Not reported
Enrollment
30 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute